NCT02392117 - Investigating the Safety and Effectiveness of Insulin Degludec in a Real World Population With Type 1 and 2 Diabetes Mellitus | Biotech Hunter

Enrollment

1,262

Participants

Timeline

Start Date

March 16, 2015

Primary Completion Date

March 19, 2018

Study Completion Date

March 19, 2018

Conditions

DiabetesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2

Interventions

DRUG

insulin degludec

Tresiba® will be prescribed by the physician under normal clinical practice conditions and will be obtained/ purchased from the chemist based on physician prescription. No treatment given.

Trial Locations (8)

8091

Novo Nordisk Investigational Site, Zurich

8200

Novo Nordisk Investigational Site, Aarhus

35122

Novo Nordisk Investigational Site, Padua

81925

Novo Nordisk Investigational Site, München

3508 GA

Novo Nordisk Investigational Site, Utrecht

07015

Novo Nordisk Investigational Site, Palma de Mallorca

651 85

Novo Nordisk Investigational Site, Karlstad

SW10 9NH

Novo Nordisk Investigational Site, London